Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities (2021 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $104.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 14.29% year-over-year to $104.0 million, compared with a TTM value of $104.0 million through Dec 2025, down 14.29%, and an annual FY2025 reading of $104.0 million, down 14.29% over the prior year.
  • Total Non-Current Liabilities was $104.0 million for Q4 2025 at Agios Pharmaceuticals, up from $101.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $164.0 million in Q3 2024 and bottomed at $88.1 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $119.4 million, with a median of $119.5 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 37.49% in 2024, then plummeted 38.23% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $145.8 million in 2021, then dropped by 7.64% to $134.6 million in 2022, then fell by 7.19% to $124.9 million in 2023, then dropped by 2.87% to $121.4 million in 2024, then dropped by 14.29% to $104.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for AGIO at $104.0 million in Q4 2025, $101.3 million in Q3 2025, and $101.6 million in Q2 2025.